Members Only
Report
COVID-19 Preparedness and Reporting in Oncology Clinical Trials: Evaluating Prospective Planning and Subsequent Toxicity Documentation -- research paper
This research examines whether cancer clinical trials were prepared to account for COVID-19 as an unexpected clinical disruption. Using data from Phase III RCTs, we analyze how COVID-19 was incorporated into trial protocols and how consistently COVID-related toxicities were later reported.